Welcome to the Post Biologic Era

David Walker & Sandra Robinson

Perspective:

- 1978 SHO Gold & Penicillamine. Erosion pre treatment
- 1984 SR 20% DMARD Sulphasalazine
- 1994 Cons 60% DMARD Methotrexate
- 2002 80% DMARD Leflunomide & TNFi & Rituximab
- 2012 90% DMARD Tocilizumab & Abatacept
- 2014 EAC

Waiting Time

- 13 weeks
- 13 weeks
- 18 weeks
- 52 weeks
- 12 weeks
- 2 weeks

Keeping the patient on boar

Here is a booklet on your diagnet
And this is what a DAS score i



- And this one....
- And this one...





Healthcare at its very best - with a personal touch

Treat to target

- Fashionable
- Works in studies but some tortology
- Difficult round the fringes: Are you really going to go for a biologic to get from 2.8 to 2.6?

Negotiating the like your DAS



nat would you

Tolerability/Adherence

- 56% to 85% of patients on a stable dose of Methotrexate are suffering from side effects.
- 51% would be attracted to a drug regime that did not include Methotrexate.
- Are they taking it?
- Most Nurses believe that patients would not be open about it.
- Most doctors don't believe that.

Does tolerance have an impact on adherence?


- In 2011 we wondered if there should be a standard for Methotrexate Tolerance
- We asked 100 patients who had never reported side effects if they suffered any

✤ 56% said yes


This audit was repeated in 6 centres across the UK

S Robinson; S Gibson; E George; U Martin; P Heslop; H Wrightson, P Prowse; M Kalinowski; D Marshall; M Reed; A Adebajo; D Walker. Tolerability and Adherence problems in patients on a stable dose of Methotrexate: Results of a multi-centre survey. Musculoskeletal Care 2015; 14,152-155.

Total Percentage of Any Side Effects



Chose or forgot to take




~70% of non-adherence is intentional¹

Gender	Cognitive ability, depression, social support, coping skills	Concerns about treatment (fear of side effects etc)
Income	Number of medicines, disease seriousness beliefs	Beliefs about illness (cause, timeline)
Age	Health literacy, locus of control	Beliefs about cost of therapy
Race	Self-efficacy, trust in HCP, HCP-patient concordance	Necessity (perceived need) for treatment
Income, personality	Symptom experience	Perceived drug efficacy

Why do Patients not tell us?

- Do not want to disappoint
- Do not think there is anything else they can take
- Are managing their disease and side effects adequately
- To not want to appear to be "breaking the rules"
- Are afraid medication will be stopped



What prompted the patient to reveal his partial adherence?

- The Health Care Professional had been chatting to the patient about side effects and revealed that an anaesthetist colleague did not adhere to treatment
- This <u>empowered</u> the patient to reveal his partial adherence to treatment for years
- It was a relief for the patient to be unburdened with this
- The result was that the patient would try to take the medication as prescribed by splitting the dose between two days returning after 3 months for follow up and change of treatment if necessary

The Importance of Identifying Non-Compliance

- Why Should Non-Adherence be a problem?
- May not even be a problem if the patient can manage their disease and remain in remission
- Poor disease control which may lead to hospitalisation in some cases
- May lead to being prescribed biologics which has increased risk and <u>cost</u>
- Poor control of Side Effects
- Missing the chance to try something which may work better
- May not have an effective partnership for disease management with their Rheumatologist/Nurse
- Fundamentally better for us to have accurate information and we can learn from the patient experience

Adherence and patient education

- Nurses do a lot of the formal patient education
- The most universal and directly necessary education is around DMARD therapy
- The "consultation" involves the transfer of knowledge which is received in the context of the patients experience and beliefs
- The aim is to improve patient concordance

National Survey

- identify the training that rheumatology nurses had received for educating patients about Methotrexate
- identify confidence in different aspects of this role
- evaluate knowledge around clinical situations relevant to Methotrexate use
- identify any need for additional training

Robinson, Sandra, Hassell, Andrew, Ryan, Sarah, Adams, Nicola and Walker, David J. (2017) *A national survey of nurse training: Confidence and competence in educating patients commencing methotrexate therapy.* Musculoskeletal Care, 15 (3). pp. 281-292. ISSN 1478-2189

Training Method

Main Training Method	Number of respondents (n= 73)	
Observing – other nurses and self directed	49 (67%)	
Observing – Rheumatologists Clinics	8 (11%)	
In-house chemotherapy course	7 (9.5%)	
In-house competencies	4 (5.5%)	
Rheumatology Course	4 (5.5%)	
Prescribing Course	1 (1.4%)	

Confidence

Confidence Level	Number of Respondents (n = 85)
Very Confident	51 (60%)
Confident	20 (24%)
Somewhat Confident	10 (12%)
Not at all Confident	4 (5%)

Conclusions

- Nurses report confidence to educate patients about Methotrexate but it takes 3 – 12 months for most to achieve this.
- Nurses use a lot of prompts in the form of leaflets and checklists which may inhibit patients from asking questions
- There is no "Gold Standard" training available, nurses have to be self motivated and resourceful in order to increase their education
- Nurses are not taught consultation techniques which involves checking perceived knowledge at intervals

An exploration of the experiences of rheumatology nurses counselling patients on methotrexate therapy <u>Sandra M. Robinson Sarah Ryan Nicola Adams</u> <u>Andrew Hassell David Walker</u> 30 August 2018 Musculoskeletal Care <u>https://doi.org/10.1002/msc.1361</u>

BIOLOGICS

- Made by living cells
- More like a whisky than a chemical
- Large proteins (antibodies or receptors)
- Directed at components of the inflammatory cascade
- Expensive to make
- Difficult to copy (Bio-similars)

Anomalies:

- Some licenced for use only with Methotrexate
- Rituximab only after TNFi
- NICE can't go against the licence
- Purchasers take a financial view

Co-morbidities

If you don't have anything that stops us treating you, then we have the tools to supress your arthritis.

Infection risk is the biggest.



Co-Morbidities


- Interesting register data showing you are 5 x less likely to go into remission if your BMI is over 30!
- You are 2.5 x less likely to go into remission if you smoke!
- Swefot database

Conclusion

- Treatment of RA has improved beyond all recognition, both in strategy for use of conventional DMARDs and use of Biologics.
- Early Arthritis Clinics are here to stay.
- There are huge challenges keeping the patients on board.
- Patients who don't need treatment tend to do very well on it!

Are we entering a Post Biologic Era?

Future therapeutic targets:




1. Mavers M et al. Curr Rheumatol Rep 2009;11(5):378-85. 2. Rommel C et al. Nat Rev Immunol 2007;7(3):191-201.

3. Taskén K et al. Physiol Rev 2004;84(1):137–67. 4. Baier G et al. Curr Opin Cell Biol 2009;21(2):262–7.

RA BEAM: Olumiant's head-to-head trial vs adalimumab with background methotrexate (MTX)

In patients with moderate-to-severe RA who have had an inadequate response to MTX (MTX-IR)¹



- 1. Taylor P, et al. N Engl J Med 2017; 376:652-62. DOI:10.1056/NEJMoa1608345.
- 2. Taylor P, et al. N Engl J Med 2017; 376:652-62. DOI:10.1056/NEJMoa1608345. (Supplementary appendix.)

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

RA-BEAM: Key inclusion and exclusion criteria

Key inclusion criteria	 Adult-onset RA, defined by ACR/EULAR 2010 criteria Inadequate response to MTX ≥ 3 erosions* * Patients with 1-2 erosions could enroll if rheumatoid factor or anti-citrullinated protein antibody was positive Stable background MTX ≥ 6/68 tender joints and ≥ 6/66 swollen joints hsCRP ≥ 6.0 mg/L
Key exclusion	Prior biologic DMARD use

Z

Taylor P, et al. N Engl J Med 2017; 376:652-62. DOI:10.1056/NEJMoa1608345.

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

criteria

RA-BEAM – ACR20 superiority over placebo

Olumiant achieved its primary endpoint - ACR20 superiority over placebo at Week 12



Taylor P, et al. N Engl J Med 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.(Supplementary appendix.) Taylor P, et al. N Engl J Med 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.



UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

RA-BEAM – ACR20 superiority over placebo Placebo + MTX (n=488) p value vs placebo + MTX ***p<0.001 | **p<0.01 | *p<0.05 % of 80 patients *** *** 74 71 70 60 *** 56 *** 51 45 40 37 *** 30 *** 20 19 0 -ACR70 ACR20 ACR50 W12 W52 W12 W24 W52 W12 W24 W24

Taylor P, et al. N Engl J Med 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.(Supplementary appendix.) Taylor P, et al. N Engl J Med 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.



UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company.

RA-BEAM – ACR 20 superiority over Adalimumab

at week 12 Olumiant + MTX demonstrated statistically significant improvements in efficacy vs Adalimumab + MTX at multiple time points over 52 weeks



Taylor P, *et al. N Engl J Med* 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.(Supplementary appendix.) Taylor P, *et al. N Engl J Med* 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.

Lilly

p value vs placebo + MTX

***p≤0.001 | **p≤0.01 | *p≤0.05


Placebo + MTX (n=488)

Olumiant 4 mg + MTX (n=48)

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

Rapid and sustained response – ACR50

Olumiant + MTX demonstrated statistically significant improvements in ACR50 compared with adalimumab + MTX at multiple time points from Week 8 to Week 52



Taylor P, *et al. N Engl J Med* 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.(Supplementary appendix.) Taylor P, *et al. N Engl J Med* 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.


UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved



Rapid and sustained response – ACR20

Olumiant + MTX demonstrated statistically significant improvements in ACR20 compared

with adalimumab + MTX at multiple time points from Week 12 to Week 52



Taylor P, *et al. N Engl J Med* 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.(Supplementary appendix.) Taylor P, *et al. N Engl J Med* 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.




UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company.

Rapid and sustained response – ACR70

Olumiant + MTX demonstrated statistically significant improvements in ACR70 compared

with adalimumab + MTX at multiple time points from Week 8 to Week 40 RA-BEAM MTX-IR patients



Taylor P, *et al. N Engl J Med* 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.(Supplementary appendix.) Taylor P, *et al. N Engl J Med* 2017; 376:652–62. DOI:10.1056/NEJMoa1608345.

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved



RA-BEAM – Patients achieving SDAI ≤11 or CDAI ≤10

p value vs placebo + MTX

***p≤0.001 | **p≤0.01 | *p≤0.05


p value vs adalimumab + MTX

Placebo + MTX (n=488)

Olumiant 4 mg + MTX (n=48)

Adalimumab + MTX (n=330)

Proportion of patients achieving SDAI ≤11 or CDAI ≤10 with Olumiant + MTX was superior to adalimumab + MTX at Week 12 and Week 52



UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

RA-BEAM: Safety



UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company.

Adverse event profile

Six placebo-controlled studies were integrated (997 patients on 4 mg Olumiant once daily and 1070 patients on placebo) to evaluate the safety of Olumiant in comparison to placebo

)[· · · · ·				
_	System organ class	Very common (≥1/10)	Common (≥1/100 to <1/10)	Uncommon (≥1/1,000 to <1/100)	
	Infections and infestations	Upper respiratory tract infections ^a	Herpes zoster Herpes simplex ^b Gastroenteritis Urinary tract infections		
	Blood and lymphatic system disorders		Thrombocytosis >600 x 10 ⁹ cells/L ^c	Neutropaenia <1 x 10 ⁹ cells/L ^c	
	Metabolism and nutrition disorders	Hypercholesterolaemia ^c		Hypertriglyceridaemia ^c	
	Gastrointestinal disorders		Nausea		
	Hepatobiliary disorders		ALT increased ≥3 x ULN ^c	AST increased $\geq 3 \times ULN^{c}$	
	Skin and subcutaneous tissue disorders			Acne	
	Investigations			Weight increased Creatine phosphokinase increased >5 x ULN	

Please consult the summary of product characteristics for further details.

^aCombined term (acute sinusitis, epiglottitis, laryngitis, nasopharyngitis, oropharyngeal pain, pharyngitis,

pharyngotonsillitis, rhinitis, sinusitis, tonsillitis, tracheitis, upper respiratory tract infection)

^bCombined term (eczema herpeticum, herpes simplex, ophthalmic herpes simplex, oral herpes)

^cIncludes changes detected during laboratory monitoring

Olumiant (baricitinib) tablets. Summary of Product Characteristics. Eli Lilly and

URBAR00107 June 2017 | © 2017 Eli Lilly and Company.



Adverse events overview: 0-24 Weeks

	RA-BEAM ¹ (MTX IR)			RA-BUILD ² (cDMARD IR)			RA-BEACON ³ (TNFi IR)		
% of Patients	PBO ^a N=488	ADAª N=330	Bari 4 mg ^a N=487	PBO⁵ N=228	Bari 2 mg ^b N=229	Bari 4 mg⁵ N=227	PBO ^c N=176	Bari 2 mg ^c N=174	Bari 4 mg ^c N=177
Serious AEs (SAEs) ^d	5	2	5	5	3	5	7	4	10
Serious infections	1	(<1)	1	2	(<1)	2	3	2	3
TEAEs	60	68	71	71	67	71	64	71	77
Discontinuation due to AE	3	2	5	4	4	5	4	4	6
Infections	27	33	36	35	31	42	31	44	40
Herpes zoster	(<1)	1	1	0	2	1	1	1	4
Malignancies, n (%)	3 (<1)	0	2 (<1)	0	0	1 (<1)	0	0	2 (1)
NMSC, n (%)	1 (<1)	0	0	0	0	1 (<1)	0	0	2(1)
MACE	0	0	(<1)	(<1)	0	0	0	0	(1)

^aParticipants taking background MTX therapy throughout the study.

^bBackground cDMARD required unless documented intolerance or contraindication [n=48 (7%)].

°Participants taking background cDMARD therapy throughout the study.


^dSAEs reported using conventional ICH definitions.

- 1. Taylor PC, et al. N Engl J Med 2017;376:652-62
- 2. Dougados M. et al. *Ann Rheum Dis* 2016;(Ahead of print). doi:10.1136/annrheumdis-2016-210094
- 3. Genovese MC, et al. N Engl J Med 2016;374:1243-52


UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

Olumiant showed no increased risk of malignancy (excluding NMSC) vs placebo or adalimumab + MTX at 24 weeks

Malignancy excluding NMSC^{1,2}



Malignancy excluding NMSC incidence rates* and 95% CI by time periods - all patients treated with Olumiant in clinical trials³



Olumiant data presented in the above figure is combined data from Phase 2 and 3 placebo

controlled studies in RA patients. Data on file: Olumiant safety information. Smolen JS, et al. Ann Rheum Dis 2016;75:412-3.

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

Olumiant data presented in above figures is combined data from

*Incidence rate was calculated as number of patients with event per 100 patient-years of observation time (including follow-up period) with Smolen JS, et al. Presentation at EULAR, June 8-11, 2016; Lorobservation time censored at the event start date

CI=confidence interval; IR=incidence rate; PT YRS=patient-years.

Olumiant showed no increased risk of serious infections vs placebo or adalimumab + MTX at 24 weeks¹⁻³

NCIDENCE RATE (95% CI)/100 PATIENT-YEARS 10 DMARD-IR1 DMARD-IR:extended MTX-IR: RA-BEAM¹ 0-24 wks Olumiant 2 vs 4 mg 0-24 wks 9 8 7 6 5 5.1 42 4 3.8 3.5 3.5 3 2.3 2 0 Placebo Olumiant Olumiant Olumiant Placebo ADA Olumiant +MTX +MTX 4 mg +MTX ALL PATIENTS 1070 997 479 479 488 487 330 WITHEVENTS 28 7 5 2 17 16 17 PATIENT-YEARS 403 417 480 551 201 217 144


Serious infection by analysis set^{1,2}

Olumiant data presented in the above figure is combined data from Phase 2 and 3 placebo

controlled studies in RA patients. Data on file: Olumiant safety information. Smolen JS, et al. Ann Rheum Dis 2016;75:412-3. Smolen JS, et al. Presentation at EULAR, June 8-11, 2016; Lorobservation time censored at the event start date

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

Serious infection incidence rates* and 95% CI by time periods - all patients treated with Olumiant in clinical trials³



Olumiant data presented in above figures is combined data from

*Incidence rate was calculated as number of patients with event per 100 patient-years of observation time (including follow-up period) with


CI=confidence interval; IR=incidence rate; PT YRS=patient-years.

The risk of herpes zoster was increased in patients treated with Olumiant vs placebo^{1–3}



Herpes zoster by analysis set^{1,2}

Herpes zoster incidence rates* and 95% CI by time periods - all patients treated with Olumiant in clinical trials³



Olumiant data presented in the above figure is combined data from Phase 2 and 3 placebo

controlled studies in RA patients. Data on file: Olumiant safety information. Smolen JS. et al. Ann Rheum Dis 2016:75:412-3.

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

Olumiant data presented in above figures is combined data from

*Incidence rate was calculated as number of patients with event per 100 patient-years of observation time (including follow-up period) with Smolen JS, et al. Presentation at EULAR, June 8-11, 2016; Lorobservation time censored at the event start date

CI=confidence interval; IR=incidence rate; PT YRS=patient-years.

Effect on Laboratory Values: 0-24 weeks

	_								
	RA-BEAM ¹ (MTX IR)			RA-BUILD ² (cDMARD IR)			RA-BEACON ³ (TNFi IR)		
CTCAE grade, n (%)	Pbo ^{b,c} (N=488)	Bari 4 mg ^c (N=487)	ADA ^c (N=330)	Pbo ^{b,c} (N=228)	Bari 2 mg ^c (N=229)	Bari 4 mg ^c (N=227)	Pbo (N=176)	Bari 2 mg (N=174)	Bari 4 mg (N=177)
Low hemoglobin count					-			-	
Grade 3: ≥6.5 to <8.0 g/dL	1 (<1)	0	1 (<1)	0	1 (<1)	0	0	1 (<1)	0
Low neutrophils count									
Grade 3: <1000 cells/mm ³	0	2 (<1)	0	1 (<1)	1 (<1)	1 (<1)	0	1 (<1)	0
Low lymphocytes count									
Grade 3: ≥200 to <500 cells/mm ³	9 (2)	4 (<1)	1 (<1)	2 (<1)	3 (1)	2 (<1)	0	2(1)	0
Elevated ALT									
Grade 3: >5X ULN and ≤20X ULN	5 (1)	3 (<1)	3 (<1)	0	2 (<1)	1 (<1)	0	0	0
Elevated creatinine									
Grade 3: >3X ULN and ≤6X ULN	0	0	0	0	0	2 (<1)	0	0	1(<1)

Data in table are n (%) patients, and indicate the worst common terminology criteria for adverse events grade in patients who experienced a treatment-emergent increase in grade at any time during the treatment period, up to the time of rescue. No patient discontinued study drug because of anemia. N = number of patients in the analysis.

Non-rescued PBO patients were switched to bari 4 mg QD at Week 24.

All patients on background MTX.

1. Taylor PC, et al. N Engl J Med 2017;376:652-62. Supplementary appendix


2. Dougados M.et al. Ann Rheum Dis. ; (Ahead of print). doi:10.1136/annrheumdis-2016-210094.

Supplementary appendix

3. Genovese MC, et al. N Engl J Med 2016;374:1243-52. Supplementary appendix

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved





Week 12 24 52 bAll patients on background MTX Taylor PC, et al. Oral Presentation American College of Rheumatology Annual Conference, 2015. Baricitinib Versus Placebo or Adalimumab in Patients with Active Rheumatoid Arthritis (RA) and an Inadequate Response to Background Methotrexate Therapy: Results of a Phase 3 Study.



UKBAR00081 April 20


Laboratory Values

Lipid s	Increase across parameters; Plateau 12 weeks	 Increase responds to statin. The effect of these elevations on the cardiovascular system has not been determined - no evident relation with MACE at the time of analysis.
Liver	ALT increase, with cDMARD background	 Most cases of hepatic transaminase elevations were asymptomatic and transient. Increased similar to those seen with adalimumab. Pattern and incidence of elevation in ALT/AST remained stable over time.
СРК	Dose- dependent increase	 Most cases were transient and did not require discontinuation. No confirmed rhabdomyolysis Elevations observed at 4 weeks and remained stable at higher value thereafter.
Rena I	Very small creatinine increase	 Increase at 2 weeks, remained stable thereafter. May be due to inhibition of creatinine secretion in renal tubules Estimates of eGFR based on creatinine may be slightly reduced without actual loss of renal function of occurrence of adverse events.

Olumiant (baricitinib) tablets. Summary of Product Characteristics. Eli Lilly and Company Ltd, 2017

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company.

Hematology



1. Olumiant (baricitinib) tablets. Summary of Product Characteristics. Eli Lilly and Company Ltd, 2017

2. Taylor PC, et al. N Engl J Med 2017;376:652-62. Supplementary appendix

UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company. All rights reserved

Practical use of Olumiant



UKBAR00107 | June 2017 | © 2017 Eli Lilly and Company.

JR Male, YOB 1948

65 ♂ Painter & Decorator, Hx L acromial neuralgia, presents with T & S MCPs & PIPs, EMS > 1hr, Rh F 217.

